Division of Gynecologic Oncology

Medicine & Life Sciences

1. Neoplasms 100%
2. Endometrioid Carcinoma 72%
3. Vulva 68%
4. Ovarian Neoplasms 67%
5. Radioimmunotherapy 62%
6. Endometrial Neoplasms 61%
7. Hysterectomy 60%
8. Uterine Cervical Neoplasms 59%
9. Oncogene Proteins 55%
10. Pandemics 47%
11. liposomal doxorubicin 46%
12. Recurrence 37%
13. Rhenium-188 34%
14. Carcinoma 33%
15. Malignant Mixed Tumor 33%
16. Survival 30%
17. Surgical Oncology 30%
18. Endometrial Hyperplasia 28%
19. Ovary 25%
20. Neoplasm Metastasis 24%
21. Adenocarcinoma 23%
22. Therapeutics 23%
23. Glutathione Peroxidase 23%
24. Quality Improvement 21%
25. Wolffian tumor 21%
26. Squamous Cell Carcinoma 20%
27. benzyloxycarbonylleucyl-leucyl-leucine aldehyde 20%
28. Transcriptome 20%
29. Antibodies 20%
30. Lutetium-177 19%
31. C1P5 monoclonal antibody 19%
32. Single Nucleotide Polymorphism 18%
33. Cod Liver Oil 18%
34. Vaginal Hysterectomy 18%
35. AIDS-related Kaposi sarcoma 18%
36. Ascites 18%
37. Genes 17%
38. Groin 17%
39. Human papillomavirus 16 17%
40. Electrosurgery 16%
41. Peutz-Jeghers Syndrome 16%
42. Papanicolaou Test 16%
43. Gestational Trophoblastic Disease 15%
44. Monoclonal Antibodies 15%
45. Clonal Evolution 15%
46. Neoplasm Antibodies 15%
47. Molecular Targeted Therapy 15%
48. Proteasome Inhibitors 15%
49. Histology 14%
50. Conservative Treatment 14%
51. Antioxidants 14%
52. Pemetrexed 14%
53. Cytoreduction Surgical Procedures 14%
54. Progression-Free Survival 13%
55. Cardiotoxicity 13%
56. Papillomaviridae 13%
57. Vagina 13%
58. Epidural Analgesia 13%
59. Paclitaxel 13%
60. Granulosa Cells 13%
61. Pathologists 13%
62. Intestinal Obstruction 13%
63. Drug Therapy 13%
64. Laparoscopy 12%
65. Ovarian Epithelial Carcinoma 12%
66. Growth 12%
67. Amenorrhea 12%
68. Bevacizumab 12%
69. Length of Stay 12%
70. Oxidation-Reduction 12%
71. Cisplatin 12%
72. Inhibins 11%
73. Lymph Nodes 11%
74. Medicine 11%
75. Transforming Growth Factors 11%
76. Genome-Wide Association Study 11%
77. Endometrium 11%
78. Microarray Analysis 11%
79. Head and Neck Neoplasms 11%
80. Radiotherapy 11%
81. Referral and Consultation 11%
82. Multiple Myeloma 11%
83. Treatment Failure 10%
84. Crohn Disease 10%
85. Sarcoma 10%
86. Disease-Free Survival 10%
87. Fertility 10%
88. Adenoma 10%
89. Teaching Hospitals 10%
90. Fingers 10%
91. University Hospitals 9%
92. Cell Biology 9%
93. Postoperative Complications 9%
94. Radiation 9%
95. Peritoneum 9%
96. Oxidants 9%
97. Pregnant Women 9%
98. Disease Progression 8%